Legend Biotech founder Frank Fan is returning to ASCO with a new CAR-T platform plan aimed at high-yield manufacturing and non-gene-editing approaches, according to reporting on his new ambition. The update follows fanfare earlier in the decade tied to a CAR-T candidate that became Carvykti. Non-gene-editing CAR-T platforms are designed to simplify manufacturing and reduce complexity in cell processing, which can be a key operational constraint for broad patient access. The company’s renewed emphasis on yield and platform repeatability suggests a focus on scaling clinical output without adding new manufacturing steps. ASCO is a key forum for competitive platform messaging in cell therapy, and the announcement positions Legend as it looks to differentiate on industrialization rather than only clinical outcomes.